Menu
Home
People
Places
Arts
History
Plants & Animals
Science
Life & Culture
Technology
Reference.org
Cathinone
open-in-new
<h2 id="history">History</h2> <h3>Discovery</h3> <p><a href="/facts/Khat/2RHjrqgf">Khat</a> has been cultivated in the <a href="/facts/Horn_of_Africa/jU4Xk52j">Horn of Africa</a> and <a href="/facts/Arabian_Peninsula/x1fDka2b">Arabian Peninsula</a> region of the world for thousands of years. It is most commonly chewed for the <a href="/facts/Euphoria/u4cnbWC4">euphoric</a> effect it produces. The active ingredient was first proposed in 1930, when <a href="/facts/Cathine/ao34ryP7">cathine</a> was identified as a predominant alkaloid in the plant.<a class="footnote-ref" id="fnref:1" href="#fn:1"><sup>1</sup></a> Cathine was thought to be the main active ingredient in khat until the 1960s, when it was found that the amount of cathine in the khat leaves is insufficient to produce the effects observed. In 1975, the United Nations Narcotic Laboratory analyzed khat leaves from <a href="/facts/Yemen/eDyoh4qV">Yemen</a>, <a href="/facts/Kenya/Y9Ko9pQu">Kenya</a> and <a href="/facts/Madagascar/ez12IAcY">Madagascar</a> and found evidence of a different alkaloid, cathinone.<a class="footnote-ref" id="fnref:2" href="#fn:2"><sup>2</sup></a> Cathinone is molecularly similar to cathine, but is much more abundant in younger plants. This finding caused scientists to speculate that cathinone was the true active ingredient in khat.<a class="footnote-ref" id="fnref:3" href="#fn:3"><sup>3</sup></a> </p><p>A study was conducted in 1994 to test the effects of cathinone. Six volunteers who had never chewed khat were given an active khat sample and a cathinone-free <a href="/facts/Placebo/3fw50t53">placebo</a> sample.<a class="footnote-ref" id="fnref:4" href="#fn:4"><sup>4</sup></a> The researchers analyzed the participants' moods, activity levels and blood pressure before and after consuming the khat or placebo. This analysis showed that cathinone produced amphetamine-like symptoms, leading the researchers to confirm that cathinone, not cathine, is the active ingredient in khat leaves.<a class="footnote-ref" id="fnref:5" href="#fn:5"><sup>5</sup></a> </p> <h3>Cultural significance</h3> <p>Over 20 million people in the <a href="/facts/Arabian_Peninsula/x1fDka2b">Arabian Peninsula</a> and <a href="/facts/East_Africa/WtsAyphI">East Africa</a> chew khat leaves daily. It is an important piece of the culture and economy in this region, especially in <a href="/facts/Ethiopia/LVujNp5v">Ethiopia</a> (where khat is said to have originated), Kenya, <a href="/facts/Djibouti/77jY0eII">Djibouti</a>, Somalia and Yemen. Men usually chew it during parties or other social gatherings while smoking cigarettes and drinking tea. Farmers and other workers also use khat in the afternoon to reduce fatigue and hunger as the day goes on. It functions like the <a href="/facts/Caffeine/Hx6E2QC5">caffeine</a> in a strong cup of coffee as an anti-fatigue drug. Students and drivers have been known to use it to stay alert for longer periods of time.<a class="footnote-ref" id="fnref:6" href="#fn:6"><sup>6</sup></a> </p><p>In order to produce its desired effects, khat leaves should be chewed fresh. The fresh leaves have a higher concentration of cathinone. Waiting too long after cultivation to chew the leaf will allow the cathinone to break down into its less potent form, cathine. Because of the need for quick chewing, it is a habit that has historically been prevalent only where the plant grows. However, in the recent years with improvements in road and air transport, khat chewing has spread to all corners of the world. </p><p>The cultivation of khat in Yemen is a highly profitable industry for farmers. Khat plants will grow differently depending on the climate they are grown in and each one will produce different amounts of cathinone.<a class="footnote-ref" id="fnref:7" href="#fn:7"><sup>7</sup></a> It generally grows best in coastal, hot climates. In Yemen, the khat plant is named after the region in which it is grown. The Nehmi khat plant has the highest known concentration of cathinone, 342.5 mg/100 g.<a class="footnote-ref" id="fnref:8" href="#fn:8"><sup>8</sup></a> </p> <h3>Legality</h3> <p>Internationally, cathinone is a <a href="/facts/Convention_on_Psychotropic_Substances/GsXhIsRg">Schedule I</a> drug under the <a href="/facts/Convention_on_Psychotropic_Substances/GsXhIsRg">Convention on Psychotropic Substances</a>.<a class="footnote-ref" id="fnref:9" href="#fn:9"><sup>9</sup></a> Circa 1993, the <a href="/facts/Drug_Enforcement_Administration/qGQpHNB8">DEA</a> added cathinone to the <a href="/facts/Controlled_Substances_Act/8laeNsgD">Controlled Substances Act</a>'s Schedule I. </p><p>The sale of khat is legal in some jurisdictions, but illegal in others (see <a href="/facts/Khat/2RHjrqgf">Khat (Regulation)</a>). <a href="/facts/Substituted_cathinone/6p5r2YLm">Substituted cathinones</a> were also often used as the key ingredient of recreational drug mixes commonly known as "<a href="/facts/Bath_salts_(drug)/HszJIQLc">bath salts</a>" in the United States.<a class="footnote-ref" id="fnref:10" href="#fn:10"><sup>10</sup></a><a class="footnote-ref" id="fnref:11" href="#fn:11"><sup>11</sup></a><a class="footnote-ref" id="fnref:12" href="#fn:12"><sup>12</sup></a><a class="footnote-ref" id="fnref:13" href="#fn:13"><sup>13</sup></a> </p><p>The table below shows the legality of khat and cathinone in various countries: </p> <table><tbody><tr><th>Region</th><th>Regulation</th></tr><tr><td>Eritrea</td><td>Legal</td></tr><tr><td>Ethiopia</td><td>Legal</td></tr><tr><td>Somalia</td><td>Legal</td></tr><tr><td>Djibouti</td><td>Legal</td></tr><tr><td>Kenya</td><td>Khat is legal but cathinone and cathine are classified as Class C substances</td></tr><tr><td>South Africa</td><td>Khat is a protected plant</td></tr><tr><td>China</td><td>Illegal</td></tr><tr><td>Israel</td><td>Legal – The khat plant leaves are allowed to be chewed and beverages containing khat are legal, but it is illegal to sell pills based on cathinone extracts</td></tr><tr><td>Malaysia</td><td>Illegal</td></tr><tr><td>Saudi Arabia</td><td>Illegal</td></tr><tr><td>Yemen</td><td>Khat is legal but the cultivation and selling of the plant is regulated by the government</td></tr><tr><td>Denmark</td><td>Illegal</td></tr><tr><td>Finland</td><td>Illegal</td></tr><tr><td>France</td><td>Khat is prohibited as a stimulant</td></tr><tr><td>Germany</td><td>Khat is illegal but a derivative of cathinone is available upon prescription</td></tr><tr><td>Ireland</td><td>Illegal unless authorized</td></tr><tr><td>Netherlands</td><td>Cathinone and cathine have been illegal but khat was announced as illegal in 2012</td></tr><tr><td>Norway</td><td>Illegal</td></tr><tr><td>Poland</td><td>Illegal</td></tr><tr><td>Sweden</td><td>Illegal</td></tr><tr><td>Switzerland</td><td>Illegal</td></tr><tr><td>United Kingdom</td><td>Illegal</td></tr><tr><td>Canada</td><td>Illegal to obtain unless approved by a medical practitioner</td></tr><tr><td>United States</td><td>Illegal</td></tr><tr><td>Australia</td><td>Illegal</td></tr><tr><td>New Zealand</td><td>Illegal</td></tr><tr><td>Georgia</td><td>The khat plant itself is allowed to be sold and chewed, but it is illegal to sell or make beverages containing khat</td></tr><tr><td>Turkey</td><td>Illegal <a class="footnote-ref" id="fnref:14" href="#fn:14"><sup>14</sup></a></td></tr><tr><td>Bulgaria</td><td>Illegal under List I - "Plants and substances with a high risk to the public health due to their harmful effect of misuse, prohibited for use in human and veterinary medicine"<a class="footnote-ref" id="fnref:15" href="#fn:15"><sup>15</sup></a></td></tr></tbody></table> <h2 id="pharmacology">Pharmacology</h2> <h3>Pharmacodynamics</h3> <a href="/facts/Monoamine_releasing_agent/JwSvmyR8">Monoamine release</a> of cathinone and related agents (<a href="/facts/Half_maximal_effective_concentration/x7oD7ITx">EC50</a>Tooltip Half maximal effective concentration, nM)<table><tbody><tr><th>Compound</th><th><a href="/facts/Norepinephrine/AjTIC9ox">NE</a>Tooltip Norepinephrine</th><th><a href="/facts/Dopamine/5gNy8Xkd">DA</a>Tooltip Dopamine</th><th><a href="/facts/Serotonin/EzY58q4a">5-HT</a>Tooltip Serotonin</th><th>Ref</th></tr><tr><td><a href="/facts/Phenethylamine/XyjysSul">Phenethylamine</a></td><td>10.9</td><td>39.5</td><td>>10,000</td><td><a class="footnote-ref" id="fnref:16" href="#fn:16"><sup>16</sup></a><a class="footnote-ref" id="fnref:17" href="#fn:17"><sup>17</sup></a><a class="footnote-ref" id="fnref:18" href="#fn:18"><sup>18</sup></a></td></tr><tr><td><a href="/facts/Amphetamine/yKIpLJ9E">Amphetamine</a></td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td> <a href="/facts/Dextroamphetamine/SoVP3mKN">Dextroamphetamine</a></td><td>6.6–7.2</td><td>5.8–24.8</td><td>698–1,765</td><td><a class="footnote-ref" id="fnref:19" href="#fn:19"><sup>19</sup></a><a class="footnote-ref" id="fnref:20" href="#fn:20"><sup>20</sup></a></td></tr><tr><td> <a href="/facts/Levoamphetamine/0fhVn75c">Levoamphetamine</a></td><td>9.5</td><td>27.7</td><td>ND</td><td><a class="footnote-ref" id="fnref:21" href="#fn:21"><sup>21</sup></a><a class="footnote-ref" id="fnref:22" href="#fn:22"><sup>22</sup></a></td></tr><tr><td><a href="/facts/Methamphetamine/vS1jloMe">Methamphetamine</a></td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td> <a href="/facts/Dextromethamphetamine/vS1jloMe">Dextromethamphetamine</a></td><td>12.3–13.8</td><td>8.5–24.5</td><td>736–1,292</td><td><a class="footnote-ref" id="fnref:23" href="#fn:23"><sup>23</sup></a><a class="footnote-ref" id="fnref:24" href="#fn:24"><sup>24</sup></a></td></tr><tr><td> <a href="/facts/Levomethamphetamine/cCyAAb1Q">Levomethamphetamine</a></td><td>28.5</td><td>416</td><td>4,640</td><td><a class="footnote-ref" id="fnref:25" href="#fn:25"><sup>25</sup></a></td></tr><tr><td>Cathinone</td><td>23.6–25.6</td><td>34.8–83.1</td><td>6,100–7,595</td><td><a class="footnote-ref" id="fnref:26" href="#fn:26"><sup>26</sup></a><a class="footnote-ref" id="fnref:27" href="#fn:27"><sup>27</sup></a><a class="footnote-ref" id="fnref:28" href="#fn:28"><sup>28</sup></a></td></tr><tr><td> D-Cathinone</td><td>72.0</td><td>184</td><td>>10,000</td><td><a class="footnote-ref" id="fnref:29" href="#fn:29"><sup>29</sup></a></td></tr><tr><td> L-Cathinone</td><td>12.4–28</td><td>18–24.6</td><td>2,366–9,267</td><td><a class="footnote-ref" id="fnref:30" href="#fn:30"><sup>30</sup></a><a class="footnote-ref" id="fnref:31" href="#fn:31"><sup>31</sup></a><a class="footnote-ref" id="fnref:32" href="#fn:32"><sup>32</sup></a></td></tr><tr><td><a href="/facts/Methcathinone/tF4VcbcI">Methcathinone</a></td><td>22–26.1</td><td>12.5–49.9</td><td>2,592–5,853</td><td><a class="footnote-ref" id="fnref:33" href="#fn:33"><sup>33</sup></a><a class="footnote-ref" id="fnref:34" href="#fn:34"><sup>34</sup></a><a class="footnote-ref" id="fnref:35" href="#fn:35"><sup>35</sup></a><a class="footnote-ref" id="fnref:36" href="#fn:36"><sup>36</sup></a><a class="footnote-ref" id="fnref:37" href="#fn:37"><sup>37</sup></a></td></tr><tr><td> D-Methcathinone</td><td>ND</td><td>ND</td><td>IA</td><td><a class="footnote-ref" id="fnref:38" href="#fn:38"><sup>38</sup></a></td></tr><tr><td> L-Methcathinone</td><td>13.1</td><td>14.8</td><td>1,772</td><td><a class="footnote-ref" id="fnref:39" href="#fn:39"><sup>39</sup></a><a class="footnote-ref" id="fnref:40" href="#fn:40"><sup>40</sup></a></td></tr><tr><td><a href="/facts/Cathine/ao34ryP7">Cathine</a></td><td>15.0</td><td>68.3</td><td>>10,000</td><td><a class="footnote-ref" id="fnref:41" href="#fn:41"><sup>41</sup></a></td></tr><tr><td colspan="5">Notes: The smaller the value, the more strongly the drug releases the neurotransmitter. The <a href="/facts/Bioassay/hRM3LIJn">assays</a> were done in rat brain <a href="/facts/Synaptosome/VTwyaNB1">synaptosomes</a> and human <a href="/facts/Potency_(pharmacology)/D38FDyPh">potencies</a> may be different. See also <a href="/facts/Monoamine_releasing_agent/JwSvmyR8">Monoamine releasing agent § Activity profiles</a> for a larger table with more compounds. Refs: <a class="footnote-ref" id="fnref:42" href="#fn:42"><sup>42</sup></a><a class="footnote-ref" id="fnref:43" href="#fn:43"><sup>43</sup></a></td></tr></tbody></table> <p>Cathinone has been found to stimulate the release of <a href="/facts/Dopamine/5gNy8Xkd">dopamine</a> and inhibit the reuptake of <a href="/facts/Epinephrine/k7vvMI7E">epinephrine</a>, <a href="/facts/Norepinephrine/AjTIC9ox">norepinephrine</a> and <a href="/facts/Serotonin/EzY58q4a">serotonin</a> in the <a href="/facts/Central_nervous_system/k8I6To97">central nervous system</a> (CNS). These <a href="/facts/Neurotransmitters/LlpYFSU3">neurotransmitters</a> are all considered <a href="/facts/Monoamine/TduN5yes">monoamines</a> and share the general structure of an <a href="/facts/Aromatic_ring/wK0DzRY6">aromatic ring</a> and an <a href="/facts/Amine/JvfYJfP6">amine</a> group attached by a two-carbon separator.<a class="footnote-ref" id="fnref:44" href="#fn:44"><sup>44</sup></a> Because cathinone is a <a href="/facts/Hydrophobic/Ifya0CXQ">hydrophobic</a> molecule, it can easily cross cell membranes and other barriers, including the <a href="/facts/Blood%E2%80%93brain_barrier/xYzvVwdu">blood–brain barrier</a>.<a class="footnote-ref" id="fnref:45" href="#fn:45"><sup>45</sup></a> This property allows it to interact with the monoamine transporters in the <a href="/facts/Synaptic_cleft/M1x5rhz7">synaptic cleft</a> between <a href="/facts/Neurons/G7CyTVdH">neurons</a>. Cathinone induces the release of <a href="/facts/Dopamine/5gNy8Xkd">dopamine</a> from brain striatal preparations that are prelabelled either with dopamine or its precursors.<a class="footnote-ref" id="fnref:46" href="#fn:46"><sup>46</sup></a> It is more specificllay a <a href="/facts/Norepinephrine%E2%80%93dopamine_releasing_agent/LRyLfF8X">norepinephrine–dopamine releasing agent</a> (NDRA) similarly to <a href="/facts/Amphetamine/yKIpLJ9E">amphetamine</a>.<a class="footnote-ref" id="fnref:47" href="#fn:47"><sup>47</sup></a><a class="footnote-ref" id="fnref:48" href="#fn:48"><sup>48</sup></a> </p><p>The metabolites of cathinone, cathine and norephedrine, also possess CNS stimulation, but create much weaker effects.<a class="footnote-ref" id="fnref:49" href="#fn:49"><sup>49</sup></a> The effects of cathinone on the body can be countered by a preceding administration of a <a href="/facts/Dopamine_receptor_antagonist/EVfsg8Na">dopamine receptor antagonist</a>.<a class="footnote-ref" id="fnref:50" href="#fn:50"><sup>50</sup></a> The antagonist prevents synaptic dopamine released by cathinone from exerting its effect by binding to dopamine receptors. </p><p>Cathinone can also affect cholinergic concentrations in the gut and airways by blocking prejunctional <a href="/facts/Adrenergic_receptor/uoAeJbcN">adrenergic receptors</a> (α2 adrenergic) and activating <a href="/facts/5-HT7/rcpLc6FL">5-HT7</a> receptors, thereby inhibiting <a href="/facts/Smooth_muscle/mpcpTsHp">smooth muscle</a> contraction.<a class="footnote-ref" id="fnref:51" href="#fn:51"><sup>51</sup></a> It can also induce dry mouth, blurred vision and increased blood pressure and heart rate.<a class="footnote-ref" id="fnref:52" href="#fn:52"><sup>52</sup></a> </p><p>Cathinone is a weak agonist of the mouse, rat, and human <a href="/facts/Trace_amine-associated_receptor_1/Xf3Qpjtw">trace amine-associated receptor 1</a> (TAAR1).<a class="footnote-ref" id="fnref:53" href="#fn:53"><sup>53</sup></a><a class="footnote-ref" id="fnref:54" href="#fn:54"><sup>54</sup></a> In contrast to cathinone however, most other <a href="/facts/Substituted_cathinone/6p5r2YLm">cathinones</a> are not human TAAR1 agonists.<a class="footnote-ref" id="fnref:55" href="#fn:55"><sup>55</sup></a><a class="footnote-ref" id="fnref:56" href="#fn:56"><sup>56</sup></a> TAAR1 activation may auto-inhibit and constrain the <a href="/facts/Monoaminergic/hoY4ra25">monoaminergic</a> effects of <a href="/facts/Monoamine_releasing_agent/JwSvmyR8">monoamine releasing agents</a> possessing TAAR1 agonism.<a class="footnote-ref" id="fnref:57" href="#fn:57"><sup>57</sup></a><a class="footnote-ref" id="fnref:58" href="#fn:58"><sup>58</sup></a> </p> <h3>Pharmacokinetics</h3> <p>Khat leaves are removed from the plant stalk and are kept in a ball in the cheek and chewed. Chewing releases juices from the leaves, which include the alkaloid cathinone. The absorption of cathinone has two phases: one in the <a href="/facts/Buccal_mucosa/uJyDj6c0">buccal mucosa</a> and one in the <a href="/facts/Stomach/Q4PPDGT6">stomach</a> and <a href="/facts/Small_intestine/1AQ8RJ4m">small intestine</a>.<a class="footnote-ref" id="fnref:59" href="#fn:59"><sup>59</sup></a> The stomach and small intestine are very important in the absorption of ingested alkaloids.<a class="footnote-ref" id="fnref:60" href="#fn:60"><sup>60</sup></a> At approximately 2.3 hours after chewing khat leaves, the maximum concentration of cathinone in blood plasma is reached. The mean residence time is 5.2 ± 3.4 hours.<a class="footnote-ref" id="fnref:61" href="#fn:61"><sup>61</sup></a> The elimination half-life of cathinone is 1.5 ± 0.8 hours.<a class="footnote-ref" id="fnref:62" href="#fn:62"><sup>62</sup></a> A two-compartment model for absorption and elimination best describes this data. However, at most, only 7% of the ingested cathinone is recovered in the urine.<a class="footnote-ref" id="fnref:63" href="#fn:63"><sup>63</sup></a> This indicates that the cathinone is being broken down in the body. Cathinone has been shown to selectively metabolize into R,S-(-)-norephedrine and cathine. The reduction of the <a href="/facts/Ketone/BqQXpLo4">ketone</a> group in cathinone will produce cathine. This reduction is catalyzed by enzymes in the liver. The spontaneous breakdown of cathinone is the reason it must be chewed fresh after cultivation.<a class="footnote-ref" id="fnref:64" href="#fn:64"><sup>64</sup></a> </p> <h3>Effects on health</h3> <p>The first documentation of the khat plant being used in medicine was in a book published by an Arabian physician in the 10th century.<a class="footnote-ref" id="fnref:65" href="#fn:65"><sup>65</sup></a> It was used as an <a href="/facts/Antidepressant/N62ND3Fa">antidepressant</a> because it led to feelings of happiness and excitement. Chronic khat chewing can also create drug dependence, as shown by animal studies.<a class="footnote-ref" id="fnref:66" href="#fn:66"><sup>66</sup></a> In such studies, monkeys were trained to push a lever to receive the drug reward. As the monkeys' dependence increased, they pressed the lever at an increasing frequency.<a class="footnote-ref" id="fnref:67" href="#fn:67"><sup>67</sup></a> </p><p>Khat chewing and the effects of cathinone on the body differ from person to person, but there is a general pattern of behavior that emerges after ingesting fresh cathinone:<a class="footnote-ref" id="fnref:68" href="#fn:68"><sup>68</sup></a> </p> <ol><li>Feelings of euphoria that last for one to two hours</li> <li>Discussion of serious issues and increased <a href="/facts/Irritability/yK49u3EP">irritability</a></li> <li>Very active imagination</li> <li>Depression</li> <li>Irritability, <a href="/facts/Loss_of_appetite/G7RsaXp9">loss of appetite</a> and <a href="/facts/Insomnia/C1TnQTb2">insomnia</a></li></ol> <p>There are other effects not related to the CNS. The chewer can develop <a href="/facts/Constipation/l4DHHM6L">constipation</a> and <a href="/facts/Heartburn/MkNPKoxS">heartburn</a> after a khat session. Long-term effects of cathinone can include <a href="/facts/Gum_disease/LFnGqDB5">gum disease</a> or <a href="/facts/Oral_cancer/ebr4WQWm">oral cancer</a>, <a href="/facts/Cardiovascular_disease/HD420nMv">cardiovascular disease</a> and <a href="/facts/Depression_(mood)/GDNFWm1L">depression</a>.<a class="footnote-ref" id="fnref:69" href="#fn:69"><sup>69</sup></a> The <a href="/facts/Withdrawal_symptoms/lGr6VEBU">withdrawal symptoms</a> of cathinone include <a href="/facts/Hot_flashes/4XyMNyFH">hot flashes</a>, <a href="/facts/Lethargy/wJFlYuB7">lethargy</a> and a great urge to use the drug for at least the first two days.<a class="footnote-ref" id="fnref:70" href="#fn:70"><sup>70</sup></a> </p> <h2 id="chemistry">Chemistry</h2> <h3>Biosynthesis</h3> <p>The synthesis of cathinone in khat begins with L-<a href="/facts/Phenylalanine/eyojfW7t">phenylalanine</a> and the first step is carried out by L-phenylalanine ammonia lyase (PAL), which cleaves off an ammonia group and creates a carbon-carbon double bond, forming <a href="/facts/Cinnamic_acid/2oBQIQIw">cinnamic acid</a>.<a class="footnote-ref" id="fnref:71" href="#fn:71"><sup>71</sup></a> After this, the molecule can either go through a beta-oxidative pathway or a non-beta-oxidative pathway. The beta-oxidative pathway produces <a href="/facts/Benzoyl-CoA/hHX2DP2W">benzoyl-CoA</a> while the non-beta-oxidative pathway produces <a href="/facts/Benzoic_acid/7HrmrBYS">benzoic acid</a>.<a class="footnote-ref" id="fnref:72" href="#fn:72"><sup>72</sup></a> Both of these molecules can be converted to 1-phenylpropane-1,2-dione by a <a href="/facts/Condensation_reaction/wMG0F6La">condensation reaction</a> catalyzed by a ThDP-dependent enzyme (Thiamine diphosphate-dependent enzyme) with <a href="/facts/Pyruvate/qJTgl4J9">pyruvate</a> and producing CO2.<a class="footnote-ref" id="fnref:73" href="#fn:73"><sup>73</sup></a> 1-phenylpropane-1,2-dione goes through a transaminase reaction to replace a ketone with an ammonia group to form (S)-cathinone. (S)-Cathinone can then undergo a reduction reaction to produce the less potent but structurally similar cathine or norephedrine, which are also found in the plant.<a class="footnote-ref" id="fnref:74" href="#fn:74"><sup>74</sup></a> </p><p>Aside from the beta- and non-beta-oxidative pathways, the biosynthesis of cathinone can proceed through a CoA-dependent pathway. The CoA-dependent pathway is actually a mix between the two main pathways as it starts like the beta-oxidative pathway and then when it loses CoA, it finishes the synthesis in the non-beta-oxidative pathway. In this pathway, the trans-cinnamic acid produced from L-phenylalanine is ligated to a <a href="/facts/Coenzyme_A/loAfeGpx">Coenzyme A</a> (CoA), just like the beginning of the beta-oxidative pathway.<a class="footnote-ref" id="fnref:75" href="#fn:75"><sup>75</sup></a> It then undergoes <a href="/facts/Hydration_reaction/T1Vb2u1d">hydration</a> at the double bond. This product then loses the CoA to produce <a href="/facts/Benzaldehyde/GyboW1KC">benzaldehyde</a>, an intermediate of the non-beta-oxidative pathway. Benzaldehyde is converted into benzoic acid and proceeds through the rest of the synthesis.<a class="footnote-ref" id="fnref:76" href="#fn:76"><sup>76</sup></a> </p> <h3>Synthetic production</h3> <p>Cathinone can be synthetically produced from propiophenone through a <a href="/facts/Friedel-Crafts/N65aEdXA">Friedel-Crafts</a> acylation of propionic acid and benzene.<a class="footnote-ref" id="fnref:77" href="#fn:77"><sup>77</sup></a> The resulting <a href="/facts/Propiophenone/d3opyrPw">propiophenone</a> can be brominated, and the bromine can be substituted with ammonia to produce a racemic mixture of cathinone. A different synthetic strategy must be employed to produce enantiomerically pure (S)-cathinone. This synthetic route starts out with the N-acetylation of the <a href="/facts/Optically_active/XQ3q2R3R">optically active</a> <a href="/facts/Amino_acid/WDxYwBny">amino acid</a>, S-alanine.<a class="footnote-ref" id="fnref:78" href="#fn:78"><sup>78</sup></a> Then, <a href="/facts/Phosphorus_pentachloride/oGLG4kDg">phosphorus pentachloride</a> (PCl5) is used to chlorinate the <a href="/facts/Carboxylic_acid/U4xuMosy">carboxylic acid</a> forming an acyl chloride. At the same time, a Friedel-Crafts acylation is preformed on benzene with <a href="/facts/Aluminum_chloride/xrhvSxDr">aluminum chloride</a> catalyst. Finally, the <a href="/facts/Acetyl/rRmtXdn3">acetyl</a> protecting group is removed by heating with <a href="/facts/Hydrochloric_acid/HqItJlUT">hydrochloric acid</a> to form enantiomerically pure S-(-)-cathinone.<a class="footnote-ref" id="fnref:79" href="#fn:79"><sup>79</sup></a> </p> <h3>Structure</h3> <p>Cathinone can be extracted from <i><a href="/facts/Catha_edulis/2RHjrqgf">Catha edulis</a></i> (khat), or synthesized from <i>α</i>-bromopropiophenone (which is easily made from <a href="/facts/Propiophenone/d3opyrPw">propiophenone</a>). Because cathinone is both a <a href="/facts/Primary_amine/SN7W44fv">primary amine</a> and a <a href="/facts/Ketone/BqQXpLo4">ketone</a>, it is very prone to <a href="/facts/Dimer_(chemistry)/mU64PnEq">dimerization</a>, especially as a free base isolated from plant matter.<a class="footnote-ref" id="fnref:80" href="#fn:80"><sup>80</sup></a><a class="footnote-ref" id="fnref:81" href="#fn:81"><sup>81</sup></a> These dimers are <a href="/facts/Pharmacological_activity/jJ14jyvc">pharmacologically inactive</a>, and the rapid dimerization reduces active amounts of cathinone in non-fresh khat.<a class="footnote-ref" id="fnref:82" href="#fn:82"><sup>82</sup></a><a class="footnote-ref" id="fnref:83" href="#fn:83"><sup>83</sup></a> The rapid formation of dimers also applies to other non-<i>N</i>-substituted cathinones such as <a href="/facts/Methylenedioxycathinone/RKT74FQI">methylenedioxycathinone</a> (MDC; normethylone).<a class="footnote-ref" id="fnref:84" href="#fn:84"><sup>84</sup></a><a class="footnote-ref" id="fnref:85" href="#fn:85"><sup>85</sup></a> </p><p>The structure of cathinone is very similar to that of other molecules. By reducing the ketone, it becomes cathine if it retains its stereochemistry, or norephedrine if its stereochemistry is inverted. Cathine is a less potent version of cathinone and cathinone's spontaneous reduction is the reason that older khat plants are not as stimulating as younger ones. Cathinone and amphetamine are closely related in that amphetamine is only lacking the ketone C=O group.<a class="footnote-ref" id="fnref:86" href="#fn:86"><sup>86</sup></a> Cathinone is structurally related to <a href="/facts/Methcathinone/tF4VcbcI">methcathinone</a>, in much the same way as <a href="/facts/Amphetamine/yKIpLJ9E">amphetamine</a> is related to <a href="/facts/Methamphetamine/vS1jloMe">methamphetamine</a>. Cathinone differs from amphetamine by possessing a <a href="/facts/Ketone/BqQXpLo4">ketone</a> <a href="/facts/Oxygen/acyn6o8r">oxygen</a> atom (C=O) on the <i>β</i> (beta) position of the side chain. Advancements in synthesizing cyclic cathinones based on α-tetralone have employed chiral HPLC-CD techniques to determine the absolute configuration of enantiomers, an approach that may contribute to the development of pharmaceutical analogs with antidepressant potential.<a class="footnote-ref" id="fnref:87" href="#fn:87"><sup>87</sup></a> The corresponding substance <a href="/facts/Cathine/ao34ryP7">cathine</a>, is a less powerful stimulant. The biophysiological conversion from cathinone to cathine is to blame for the depotentiation of <a href="/facts/Khat/2RHjrqgf">khat</a> leaves over time. Fresh leaves have a greater ratio of cathinone to cathine than dried ones, therefore having more psychoactive effects. </p><p>There are many cathinone derivatives that include the addition of an R group to the amino end of the molecule. Some of these derivatives have medical uses as well. <a href="/facts/Bupropion/wjWDPxmr">Bupropion</a> is one of the most commonly prescribed antidepressants and its structure is Cathinone with a tertiary butyl group attached to the nitrogen and chlorine attached to the benzene ring <a href="/facts/Meta-_(chemistry)/o88a4KQ2">meta-</a> to the main carbon chain.<a class="footnote-ref" id="fnref:88" href="#fn:88"><sup>88</sup></a> </p><p>Other cathinone derivatives are strong psychoactive drugs. One such drug is <a href="/facts/Methylone/hR76hg7c">methylone</a>, a drug structurally similar to <a href="/facts/MDMA/WYDACxGN">MDMA</a>. </p> <h2 id="see-also">See also</h2> <ul><li><a href="/facts/Bupropion/wjWDPxmr">Bupropion</a></li> <li><a href="/facts/Central_nervous_system/k8I6To97">Central nervous system</a></li> <li><a href="/facts/Khat/2RHjrqgf">Khat</a></li> <li><a href="/facts/Substituted_cathinone/6p5r2YLm">Substituted cathinone</a></li></ul> <h2 id="external-links">External links</h2> <ul><li><a href="http://www.erowid.org/chemicals/cathinone/">Erowid Cathinone Vault</a> <a href="https://web.archive.org/web/20080622214102/https://www.erowid.org/chemicals/cathinone/">Archived</a> 2008-06-22 at the <a href="/facts/Wayback_Machine/nmQ3a6JC">Wayback Machine</a></li> <li><a href="https://www.theguardian.com/israel/Story/0,2763,1296958,00.html">Cathinone Popularity Soars in Israel</a></li></ul> <h2 id="references">References</h2> <ol> <li id="fn:1"><p>Patel NB (June 2000). "Mechanism of action of cathinone: the active ingredient of khat (Catha edulis)". East African Medical Journal. 77 (6): 329–332. doi:10.4314/eamj.v77i6.46651. PMID 12858935. <a href="https://doi.org/10.4314%2Feamj.v77i6.46651" target="_blank">https://doi.org/10.4314%2Feamj.v77i6.46651</a> <a href="#fnref:1" class="footnote-back-ref">↩</a></p></li> <li id="fn:2"><p>Patel NB (June 2000). "Mechanism of action of cathinone: the active ingredient of khat (Catha edulis)". East African Medical Journal. 77 (6): 329–332. doi:10.4314/eamj.v77i6.46651. PMID 12858935. <a href="https://doi.org/10.4314%2Feamj.v77i6.46651" target="_blank">https://doi.org/10.4314%2Feamj.v77i6.46651</a> <a href="#fnref:2" class="footnote-back-ref">↩</a></p></li> <li id="fn:3"><p>Patel NB (June 2000). "Mechanism of action of cathinone: the active ingredient of khat (Catha edulis)". East African Medical Journal. 77 (6): 329–332. doi:10.4314/eamj.v77i6.46651. PMID 12858935. <a href="https://doi.org/10.4314%2Feamj.v77i6.46651" target="_blank">https://doi.org/10.4314%2Feamj.v77i6.46651</a> <a href="#fnref:3" class="footnote-back-ref">↩</a></p></li> <li id="fn:4"><p>Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU (May 1994). "Pharmacodynamics and pharmacokinetics of khat: a controlled study". Clinical Pharmacology and Therapeutics. 55 (5): 556–562. doi:10.1038/clpt.1994.69. PMID 7910126. S2CID 25788465. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:4" class="footnote-back-ref">↩</a></p></li> <li id="fn:5"><p>Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU (May 1994). "Pharmacodynamics and pharmacokinetics of khat: a controlled study". Clinical Pharmacology and Therapeutics. 55 (5): 556–562. doi:10.1038/clpt.1994.69. PMID 7910126. S2CID 25788465. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:5" class="footnote-back-ref">↩</a></p></li> <li id="fn:6"><p>Kirby A (7 April 2007). "Yemen's khat habit soaks up water". BBC News. BBC. Archived from the original on 12 October 2014. Retrieved 20 March 2015. <a href="http://news.bbc.co.uk/2/hi/programmes/from_our_own_correspondent/6530453.stm" target="_blank">http://news.bbc.co.uk/2/hi/programmes/from_our_own_correspondent/6530453.stm</a> <a href="#fnref:6" class="footnote-back-ref">↩</a></p></li> <li id="fn:7"><p>Al-Motarreb A, Baker K, Broadley KJ (August 2002). "Khat: pharmacological and medical aspects and its social use in Yemen". Phytotherapy Research. 16 (5): 403–413. doi:10.1002/ptr.1106. PMID 12203257. S2CID 9749292. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:7" class="footnote-back-ref">↩</a></p></li> <li id="fn:8"><p>Al-Motarreb A, Baker K, Broadley KJ (August 2002). "Khat: pharmacological and medical aspects and its social use in Yemen". Phytotherapy Research. 16 (5): 403–413. doi:10.1002/ptr.1106. PMID 12203257. S2CID 9749292. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:8" class="footnote-back-ref">↩</a></p></li> <li id="fn:9"><p>"List of psychotropic substances under international control" (PDF). International Narcotics Control Board. United Nations. 2003. Archived from the original (PDF) on 2012-08-31. <a href="https://web.archive.org/web/20120831222336/http://www.incb.org/pdf/e/list/green.pdf" target="_blank">https://web.archive.org/web/20120831222336/http://www.incb.org/pdf/e/list/green.pdf</a> <a href="#fnref:9" class="footnote-back-ref">↩</a></p></li> <li id="fn:10"><p>"Synthetic Street Drug Camouflaged as Bath Salts Has Dangerous, Bizarre Effects". PBS NewsHour. 20 September 2012. Archived from the original on 29 December 2012. Retrieved 7 December 2013. <a href="https://web.archive.org/web/20121229055853/https://www.pbs.org/newshour/bb/science/july-dec12/bathsalts_09-20.html" target="_blank">https://web.archive.org/web/20121229055853/https://www.pbs.org/newshour/bb/science/july-dec12/bathsalts_09-20.html</a> <a href="#fnref:10" class="footnote-back-ref">↩</a></p></li> <li id="fn:11"><p>Urquhart C (4 September 2004). "Drugs and dance as Israelis blot out intifada". The Guardian. Archived from the original on 8 November 2016. Retrieved 19 April 2015. <a href="https://web.archive.org/web/20161108053442/https://www.theguardian.com/world/2004/sep/04/israel" target="_blank">https://web.archive.org/web/20161108053442/https://www.theguardian.com/world/2004/sep/04/israel</a> <a href="#fnref:11" class="footnote-back-ref">↩</a></p></li> <li id="fn:12"><p>Chai C (16 April 2015). "What you need to know about flakka, the latest drug causing erratic behaviour". Globalnews.ca. Archived from the original on 20 April 2015. Retrieved 19 April 2015. <a href="https://web.archive.org/web/20150420001955/http://globalnews.ca/news/1942263/what-you-need-to-know-about-flakka-the-latest-drug-causing-erratic-behaviour/" target="_blank">https://web.archive.org/web/20150420001955/http://globalnews.ca/news/1942263/what-you-need-to-know-about-flakka-the-latest-drug-causing-erratic-behaviour/</a> <a href="#fnref:12" class="footnote-back-ref">↩</a></p></li> <li id="fn:13"><p>Extance A. "The rising tide of 'legal highs'". Chemistry World. Archived from the original on 3 August 2018. Retrieved 3 August 2018. <a href="https://www.chemistryworld.com/feature/the-rising-tide-of-legal-highs/3007738.article" target="_blank">https://www.chemistryworld.com/feature/the-rising-tide-of-legal-highs/3007738.article</a> <a href="#fnref:13" class="footnote-back-ref">↩</a></p></li> <li id="fn:14"><p>"Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü". www.resmigazete.gov.tr. <a href="https://www.resmigazete.gov.tr/eskiler/2011/02/20110213-4.htm" target="_blank">https://www.resmigazete.gov.tr/eskiler/2011/02/20110213-4.htm</a> <a href="#fnref:14" class="footnote-back-ref">↩</a></p></li> <li id="fn:15"><p>"НАРЕДБА за реда за класифициране на растенията и веществата като наркотични" [REGULATION on the procedure for classifying plants and substances as narcotic] (PDF). Ministry of Health (in Bulgarian). Republic of Bulgaria. Archived (PDF) from the original on 2017-08-27. Retrieved 2017-08-26. <a href="http://www.mh.government.bg/media/filer_public/2015/06/19/naredba-red-za-klasifitsirane-na-rasteniyata-i-veshtestvata-kato-narkotichni-08-11-2013.pdf" target="_blank">http://www.mh.government.bg/media/filer_public/2015/06/19/naredba-red-za-klasifitsirane-na-rasteniyata-i-veshtestvata-kato-narkotichni-08-11-2013.pdf</a> <a href="#fnref:15" class="footnote-back-ref">↩</a></p></li> <li id="fn:16"><p>Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, et al. (February 2015). "Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter". Drug and Alcohol Dependence. 147: 1–19. doi:10.1016/j.drugalcdep.2014.12.005. PMC 4297708. PMID 25548026. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297708" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297708</a> <a href="#fnref:16" class="footnote-back-ref">↩</a></p></li> <li id="fn:17"><p>Forsyth AN (22 May 2012). "Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines". ScholarWorks@UNO. Retrieved 4 November 2024. <a href="https://scholarworks.uno.edu/td/1436/" target="_blank">https://scholarworks.uno.edu/td/1436/</a> <a href="#fnref:17" class="footnote-back-ref">↩</a></p></li> <li id="fn:18"><p>Blough B (July 2008). "Dopamine-releasing agents" (PDF). In Trudell ML, Izenwasser S (eds.). Dopamine Transporters: Chemistry, Biology and Pharmacology. Hoboken [NJ]: Wiley. pp. 305–320. ISBN 978-0-470-11790-3. OCLC 181862653. OL 18589888W. <a href="978-0-470-11790-3" target="_blank">978-0-470-11790-3</a> <a href="#fnref:18" class="footnote-back-ref">↩</a></p></li> <li id="fn:19"><p>Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID 11071707. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:19" class="footnote-back-ref">↩</a></p></li> <li id="fn:20"><p>Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, et al. (2013). "Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products". Neuropsychopharmacology. 38 (4): 552–562. doi:10.1038/npp.2012.204. PMC 3572453. PMID 23072836. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572453" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572453</a> <a href="#fnref:20" class="footnote-back-ref">↩</a></p></li> <li id="fn:21"><p>Forsyth AN (22 May 2012). "Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines". ScholarWorks@UNO. Retrieved 4 November 2024. <a href="https://scholarworks.uno.edu/td/1436/" target="_blank">https://scholarworks.uno.edu/td/1436/</a> <a href="#fnref:21" class="footnote-back-ref">↩</a></p></li> <li id="fn:22"><p>Blough B (July 2008). "Dopamine-releasing agents" (PDF). In Trudell ML, Izenwasser S (eds.). Dopamine Transporters: Chemistry, Biology and Pharmacology. Hoboken [NJ]: Wiley. pp. 305–320. ISBN 978-0-470-11790-3. OCLC 181862653. OL 18589888W. <a href="978-0-470-11790-3" target="_blank">978-0-470-11790-3</a> <a href="#fnref:22" class="footnote-back-ref">↩</a></p></li> <li id="fn:23"><p>Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID 11071707. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:23" class="footnote-back-ref">↩</a></p></li> <li id="fn:24"><p>Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. (2012). "The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue". Neuropsychopharmacology. 37 (5): 1192–1203. doi:10.1038/npp.2011.304. PMC 3306880. PMID 22169943. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306880" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306880</a> <a href="#fnref:24" class="footnote-back-ref">↩</a></p></li> <li id="fn:25"><p>Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID 11071707. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:25" class="footnote-back-ref">↩</a></p></li> <li id="fn:26"><p>Blough B (July 2008). "Dopamine-releasing agents" (PDF). In Trudell ML, Izenwasser S (eds.). Dopamine Transporters: Chemistry, Biology and Pharmacology. Hoboken [NJ]: Wiley. pp. 305–320. ISBN 978-0-470-11790-3. OCLC 181862653. OL 18589888W. <a href="978-0-470-11790-3" target="_blank">978-0-470-11790-3</a> <a href="#fnref:26" class="footnote-back-ref">↩</a></p></li> <li id="fn:27"><p>Blough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, et al. (March 2019). "The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes". Psychopharmacology. 236 (3): 915–924. doi:10.1007/s00213-018-5063-9. PMC 6475490. PMID 30341459. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475490" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475490</a> <a href="#fnref:27" class="footnote-back-ref">↩</a></p></li> <li id="fn:28"><p>Fitzgerald LR, Gannon BM, Walther D, Landavazo A, Hiranita T, Blough BE, et al. (March 2024). "Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones". Neuropharmacology. 245: 109827. doi:10.1016/j.neuropharm.2023.109827. PMC 10842458. PMID 38154512. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10842458" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10842458</a> <a href="#fnref:28" class="footnote-back-ref">↩</a></p></li> <li id="fn:29"><p>Hutsell BA, Baumann MH, Partilla JS, Banks ML, Vekariya R, Glennon RA, et al. (February 2016). "Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats". Eur Neuropsychopharmacol. 26 (2): 288–297. doi:10.1016/j.euroneuro.2015.12.010. PMC 5331761. PMID 26738428. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331761" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331761</a> <a href="#fnref:29" class="footnote-back-ref">↩</a></p></li> <li id="fn:30"><p>Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, et al. (October 2003). "In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates". The Journal of Pharmacology and Experimental Therapeutics. 307 (1): 138–145. doi:10.1124/jpet.103.053975. PMID 12954796. S2CID 19015584. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:30" class="footnote-back-ref">↩</a></p></li> <li id="fn:31"><p>Shalabi AR, Walther D, Baumann MH, Glennon RA (June 2017). "Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release". ACS Chem Neurosci. 8 (6): 1397–1403. doi:10.1021/acschemneuro.7b00055. PMC 7261150. PMID 28220701. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261150" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261150</a> <a href="#fnref:31" class="footnote-back-ref">↩</a></p></li> <li id="fn:32"><p>Hutsell BA, Baumann MH, Partilla JS, Banks ML, Vekariya R, Glennon RA, et al. (February 2016). "Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats". Eur Neuropsychopharmacol. 26 (2): 288–297. doi:10.1016/j.euroneuro.2015.12.010. PMC 5331761. PMID 26738428. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331761" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331761</a> <a href="#fnref:32" class="footnote-back-ref">↩</a></p></li> <li id="fn:33"><p>Blough B (July 2008). "Dopamine-releasing agents" (PDF). In Trudell ML, Izenwasser S (eds.). Dopamine Transporters: Chemistry, Biology and Pharmacology. Hoboken [NJ]: Wiley. pp. 305–320. ISBN 978-0-470-11790-3. OCLC 181862653. OL 18589888W. <a href="978-0-470-11790-3" target="_blank">978-0-470-11790-3</a> <a href="#fnref:33" class="footnote-back-ref">↩</a></p></li> <li id="fn:34"><p>Blough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, et al. (March 2019). "The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes". Psychopharmacology. 236 (3): 915–924. doi:10.1007/s00213-018-5063-9. PMC 6475490. PMID 30341459. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475490" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475490</a> <a href="#fnref:34" class="footnote-back-ref">↩</a></p></li> <li id="fn:35"><p>Shalabi AR (14 December 2017). Structure-Activity Relationship Studies of Bupropion and Related 3-Substituted Methcathinone Analogues at Monoamine Transporters. VCU Scholars Compass (Thesis). doi:10.25772/M4E1-3549. Retrieved 24 November 2024. <a href="https://scholarscompass.vcu.edu/etd/5176/" target="_blank">https://scholarscompass.vcu.edu/etd/5176/</a> <a href="#fnref:35" class="footnote-back-ref">↩</a></p></li> <li id="fn:36"><p>Walther D, Shalabi AR, Baumann MH, Glennon RA (January 2019). "Systematic Structure-Activity Studies on Selected 2-, 3-, and 4-Monosubstituted Synthetic Methcathinone Analogs as Monoamine Transporter Releasing Agents". ACS Chem Neurosci. 10 (1): 740–745. doi:10.1021/acschemneuro.8b00524. PMC 8269283. PMID 30354055. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269283" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269283</a> <a href="#fnref:36" class="footnote-back-ref">↩</a></p></li> <li id="fn:37"><p>Fitzgerald LR, Gannon BM, Walther D, Landavazo A, Hiranita T, Blough BE, et al. (March 2024). "Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones". Neuropharmacology. 245: 109827. doi:10.1016/j.neuropharm.2023.109827. PMC 10842458. PMID 38154512. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10842458" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10842458</a> <a href="#fnref:37" class="footnote-back-ref">↩</a></p></li> <li id="fn:38"><p>Davies RA (10 July 2019). Structure-Activity Relationship Studies of Synthetic Cathinones and Related Agents. VCU Scholars Compass (Thesis). doi:10.25772/TZSA-0396. Retrieved 24 November 2024. <a href="https://scholarscompass.vcu.edu/etd/5953/" target="_blank">https://scholarscompass.vcu.edu/etd/5953/</a> <a href="#fnref:38" class="footnote-back-ref">↩</a></p></li> <li id="fn:39"><p>Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, et al. (October 2003). "In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates". The Journal of Pharmacology and Experimental Therapeutics. 307 (1): 138–145. doi:10.1124/jpet.103.053975. PMID 12954796. S2CID 19015584. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:39" class="footnote-back-ref">↩</a></p></li> <li id="fn:40"><p>Glennon RA, Dukat M (2017). "Structure-Activity Relationships of Synthetic Cathinones". Neuropharmacology of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences. Vol. 32. Springer. pp. 19–47. doi:10.1007/7854_2016_41. ISBN 978-3-319-52442-9. PMC 5818155. PMID 27830576. <a href="978-3-319-52442-9" target="_blank">978-3-319-52442-9</a> <a href="#fnref:40" class="footnote-back-ref">↩</a></p></li> <li id="fn:41"><p>Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, et al. (October 2003). "In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates". The Journal of Pharmacology and Experimental Therapeutics. 307 (1): 138–145. doi:10.1124/jpet.103.053975. PMID 12954796. S2CID 19015584. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:41" class="footnote-back-ref">↩</a></p></li> <li id="fn:42"><p>Rothman RB, Baumann MH (October 2003). "Monoamine transporters and psychostimulant drugs". Eur J Pharmacol. 479 (1–3): 23–40. doi:10.1016/j.ejphar.2003.08.054. PMID 14612135. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:42" class="footnote-back-ref">↩</a></p></li> <li id="fn:43"><p>Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry. 6 (17): 1845–1859. doi:10.2174/156802606778249766. PMID 17017961. <a href="https://zenodo.org/record/1235860" target="_blank">https://zenodo.org/record/1235860</a> <a href="#fnref:43" class="footnote-back-ref">↩</a></p></li> <li id="fn:44"><p>Al-Motarreb A, Baker K, Broadley KJ (August 2002). "Khat: pharmacological and medical aspects and its social use in Yemen". Phytotherapy Research. 16 (5): 403–413. doi:10.1002/ptr.1106. PMID 12203257. S2CID 9749292. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:44" class="footnote-back-ref">↩</a></p></li> <li id="fn:45"><p>Hugins KB (17 July 2014). "Cathinone: History, Synthesis, and Human Applications". slideshare. Archived from the original on 4 July 2015. Retrieved 8 March 2015. <a href="https://www.slideshare.net/KevinHugins/cathinone-history-synthesis-and-human-applications" target="_blank">https://www.slideshare.net/KevinHugins/cathinone-history-synthesis-and-human-applications</a> <a href="#fnref:45" class="footnote-back-ref">↩</a></p></li> <li id="fn:46"><p>Kalix P (1981). "Cathinone, an alkaloid from khat leaves with an amphetamine-like releasing effect". Psychopharmacology. 74 (3): 269–270. doi:10.1007/BF00427108. PMID 6791236. S2CID 20621923. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:46" class="footnote-back-ref">↩</a></p></li> <li id="fn:47"><p>Rothman RB, Baumann MH (October 2003). "Monoamine transporters and psychostimulant drugs". Eur J Pharmacol. 479 (1–3): 23–40. doi:10.1016/j.ejphar.2003.08.054. PMID 14612135. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:47" class="footnote-back-ref">↩</a></p></li> <li id="fn:48"><p>Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry. 6 (17): 1845–1859. doi:10.2174/156802606778249766. PMID 17017961. <a href="https://zenodo.org/record/1235860" target="_blank">https://zenodo.org/record/1235860</a> <a href="#fnref:48" class="footnote-back-ref">↩</a></p></li> <li id="fn:49"><p>"Cathinone". Drug Bank. Archived from the original on 23 April 2015. Retrieved 10 March 2015. <a href="http://www.drugbank.ca/drugs/DB01560" target="_blank">http://www.drugbank.ca/drugs/DB01560</a> <a href="#fnref:49" class="footnote-back-ref">↩</a></p></li> <li id="fn:50"><p>"Cathinone". Drug Bank. Archived from the original on 23 April 2015. Retrieved 10 March 2015. <a href="http://www.drugbank.ca/drugs/DB01560" target="_blank">http://www.drugbank.ca/drugs/DB01560</a> <a href="#fnref:50" class="footnote-back-ref">↩</a></p></li> <li id="fn:51"><p>Hugins KB (17 July 2014). "Cathinone: History, Synthesis, and Human Applications". slideshare. Archived from the original on 4 July 2015. Retrieved 8 March 2015. <a href="https://www.slideshare.net/KevinHugins/cathinone-history-synthesis-and-human-applications" target="_blank">https://www.slideshare.net/KevinHugins/cathinone-history-synthesis-and-human-applications</a> <a href="#fnref:51" class="footnote-back-ref">↩</a></p></li> <li id="fn:52"><p>Al-Motarreb A, Baker K, Broadley KJ (August 2002). "Khat: pharmacological and medical aspects and its social use in Yemen". Phytotherapy Research. 16 (5): 403–413. doi:10.1002/ptr.1106. PMID 12203257. S2CID 9749292. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:52" class="footnote-back-ref">↩</a></p></li> <li id="fn:53"><p>Gainetdinov RR, Hoener MC, Berry MD (July 2018). "Trace Amines and Their Receptors". Pharmacol Rev. 70 (3): 549–620. doi:10.1124/pr.117.015305. PMID 29941461. <a href="https://doi.org/10.1124%2Fpr.117.015305" target="_blank">https://doi.org/10.1124%2Fpr.117.015305</a> <a href="#fnref:53" class="footnote-back-ref">↩</a></p></li> <li id="fn:54"><p>Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther. 357 (1): 134–144. doi:10.1124/jpet.115.229765. PMID 26791601. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:54" class="footnote-back-ref">↩</a></p></li> <li id="fn:55"><p>Kuropka P, Zawadzki M, Szpot P (May 2023). "A narrative review of the neuropharmacology of synthetic cathinones-Popular alternatives to classical drugs of abuse". Hum Psychopharmacol. 38 (3): e2866. doi:10.1002/hup.2866. PMID 36866677. Another feature that distinguishes [synthetic cathinones (SCs)] from amphetamines is their negligible interaction with the trace amine associated receptor 1 (TAAR1). Activation of this receptor reduces the activity of dopaminergic neurones, thereby reducing psychostimulatory effects and addictive potential (Miller, 2011; Simmler et al., 2016). Amphetamines are potent agonists of this receptor, making them likely to self‐inhibit their stimulating effects. In contrast, SCs show negligible activity towards TAAR1 (Kolaczynska et al., 2021; Rickli et al., 2015; Simmler et al., 2014, 2016). [...] It is worth noting, however, that for TAAR1 there is considerable species variability in its interaction with ligands, and it is possible that the in vitro activity of [rodent TAAR1 agonists] may not translate into activity in the human body (Simmler et al., 2016). The lack of self‐regulation by TAAR1 may partly explain the higher addictive potential of SCs compared to amphetamines (Miller, 2011; Simmler et al., 2013). <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:55" class="footnote-back-ref">↩</a></p></li> <li id="fn:56"><p>Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther. 357 (1): 134–144. doi:10.1124/jpet.115.229765. PMID 26791601. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:56" class="footnote-back-ref">↩</a></p></li> <li id="fn:57"><p>Kuropka P, Zawadzki M, Szpot P (May 2023). "A narrative review of the neuropharmacology of synthetic cathinones-Popular alternatives to classical drugs of abuse". Hum Psychopharmacol. 38 (3): e2866. doi:10.1002/hup.2866. PMID 36866677. Another feature that distinguishes [synthetic cathinones (SCs)] from amphetamines is their negligible interaction with the trace amine associated receptor 1 (TAAR1). Activation of this receptor reduces the activity of dopaminergic neurones, thereby reducing psychostimulatory effects and addictive potential (Miller, 2011; Simmler et al., 2016). Amphetamines are potent agonists of this receptor, making them likely to self‐inhibit their stimulating effects. In contrast, SCs show negligible activity towards TAAR1 (Kolaczynska et al., 2021; Rickli et al., 2015; Simmler et al., 2014, 2016). [...] It is worth noting, however, that for TAAR1 there is considerable species variability in its interaction with ligands, and it is possible that the in vitro activity of [rodent TAAR1 agonists] may not translate into activity in the human body (Simmler et al., 2016). The lack of self‐regulation by TAAR1 may partly explain the higher addictive potential of SCs compared to amphetamines (Miller, 2011; Simmler et al., 2013). <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:57" class="footnote-back-ref">↩</a></p></li> <li id="fn:58"><p>Espinoza S, Gainetdinov RR (2014). "Neuronal Functions and Emerging Pharmacology of TAAR1". Taste and Smell. Topics in Medicinal Chemistry. Vol. 23. Cham: Springer International Publishing. pp. 175–194. doi:10.1007/7355_2014_78. ISBN 978-3-319-48925-4. Interestingly, the concentrations of amphetamine found to be necessary to activate TAAR1 are in line with what was found in drug abusers [3, 51, 52]. Thus, it is likely that some of the effects produced by amphetamines could be mediated by TAAR1. Indeed, in a study in mice, MDMA effects were found to be mediated in part by TAAR1, in a sense that MDMA auto-inhibits its neurochemical and functional actions [46]. Based on this and other studies (see other section), it has been suggested that TAAR1 could play a role in reward mechanisms and that amphetamine activity on TAAR1 counteracts their known behavioral and neurochemical effects mediated via dopamine neurotransmission. <a href="978-3-319-48925-4" target="_blank">978-3-319-48925-4</a> <a href="#fnref:58" class="footnote-back-ref">↩</a></p></li> <li id="fn:59"><p>Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU (May 1994). "Pharmacodynamics and pharmacokinetics of khat: a controlled study". Clinical Pharmacology and Therapeutics. 55 (5): 556–562. doi:10.1038/clpt.1994.69. PMID 7910126. S2CID 25788465. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:59" class="footnote-back-ref">↩</a></p></li> <li id="fn:60"><p>Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU (May 1994). "Pharmacodynamics and pharmacokinetics of khat: a controlled study". Clinical Pharmacology and Therapeutics. 55 (5): 556–562. doi:10.1038/clpt.1994.69. PMID 7910126. S2CID 25788465. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:60" class="footnote-back-ref">↩</a></p></li> <li id="fn:61"><p>Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU (May 1994). "Pharmacodynamics and pharmacokinetics of khat: a controlled study". Clinical Pharmacology and Therapeutics. 55 (5): 556–562. doi:10.1038/clpt.1994.69. PMID 7910126. S2CID 25788465. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:61" class="footnote-back-ref">↩</a></p></li> <li id="fn:62"><p>Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU (May 1994). "Pharmacodynamics and pharmacokinetics of khat: a controlled study". Clinical Pharmacology and Therapeutics. 55 (5): 556–562. doi:10.1038/clpt.1994.69. PMID 7910126. S2CID 25788465. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:62" class="footnote-back-ref">↩</a></p></li> <li id="fn:63"><p>Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU (May 1994). "Pharmacodynamics and pharmacokinetics of khat: a controlled study". Clinical Pharmacology and Therapeutics. 55 (5): 556–562. doi:10.1038/clpt.1994.69. PMID 7910126. S2CID 25788465. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:63" class="footnote-back-ref">↩</a></p></li> <li id="fn:64"><p>Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU (May 1994). "Pharmacodynamics and pharmacokinetics of khat: a controlled study". Clinical Pharmacology and Therapeutics. 55 (5): 556–562. doi:10.1038/clpt.1994.69. PMID 7910126. S2CID 25788465. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:64" class="footnote-back-ref">↩</a></p></li> <li id="fn:65"><p>Al-Motarreb A, Baker K, Broadley KJ (August 2002). "Khat: pharmacological and medical aspects and its social use in Yemen". Phytotherapy Research. 16 (5): 403–413. doi:10.1002/ptr.1106. PMID 12203257. S2CID 9749292. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:65" class="footnote-back-ref">↩</a></p></li> <li id="fn:66"><p>Al-Motarreb A, Baker K, Broadley KJ (August 2002). "Khat: pharmacological and medical aspects and its social use in Yemen". Phytotherapy Research. 16 (5): 403–413. doi:10.1002/ptr.1106. PMID 12203257. S2CID 9749292. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:66" class="footnote-back-ref">↩</a></p></li> <li id="fn:67"><p>Al-Motarreb A, Baker K, Broadley KJ (August 2002). "Khat: pharmacological and medical aspects and its social use in Yemen". Phytotherapy Research. 16 (5): 403–413. doi:10.1002/ptr.1106. PMID 12203257. S2CID 9749292. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:67" class="footnote-back-ref">↩</a></p></li> <li id="fn:68"><p>Al-Motarreb A, Baker K, Broadley KJ (August 2002). "Khat: pharmacological and medical aspects and its social use in Yemen". Phytotherapy Research. 16 (5): 403–413. doi:10.1002/ptr.1106. PMID 12203257. S2CID 9749292. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:68" class="footnote-back-ref">↩</a></p></li> <li id="fn:69"><p>Al-Motarreb A, Baker K, Broadley KJ (August 2002). "Khat: pharmacological and medical aspects and its social use in Yemen". Phytotherapy Research. 16 (5): 403–413. doi:10.1002/ptr.1106. PMID 12203257. S2CID 9749292. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:69" class="footnote-back-ref">↩</a></p></li> <li id="fn:70"><p>Al-Motarreb A, Baker K, Broadley KJ (August 2002). "Khat: pharmacological and medical aspects and its social use in Yemen". Phytotherapy Research. 16 (5): 403–413. doi:10.1002/ptr.1106. PMID 12203257. S2CID 9749292. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:70" class="footnote-back-ref">↩</a></p></li> <li id="fn:71"><p>Hagel JM, Krizevski R, Kilpatrick K, Sitrit Y, Marsolais F, Lewinsohn E, et al. (October 2011). "Expressed sequence tag analysis of khat (Catha edulis) provides a putative molecular biochemical basis for the biosynthesis of phenylpropylamino alkaloids". Genetics and Molecular Biology. 34 (4): 640–646. doi:10.1590/S1415-47572011000400017. PMC 3229120. PMID 22215969. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229120" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229120</a> <a href="#fnref:71" class="footnote-back-ref">↩</a></p></li> <li id="fn:72"><p>Hagel JM, Krizevski R, Kilpatrick K, Sitrit Y, Marsolais F, Lewinsohn E, et al. (October 2011). "Expressed sequence tag analysis of khat (Catha edulis) provides a putative molecular biochemical basis for the biosynthesis of phenylpropylamino alkaloids". Genetics and Molecular Biology. 34 (4): 640–646. doi:10.1590/S1415-47572011000400017. PMC 3229120. PMID 22215969. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229120" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229120</a> <a href="#fnref:72" class="footnote-back-ref">↩</a></p></li> <li id="fn:73"><p>Hagel JM, Krizevski R, Kilpatrick K, Sitrit Y, Marsolais F, Lewinsohn E, et al. (October 2011). "Expressed sequence tag analysis of khat (Catha edulis) provides a putative molecular biochemical basis for the biosynthesis of phenylpropylamino alkaloids". Genetics and Molecular Biology. 34 (4): 640–646. doi:10.1590/S1415-47572011000400017. PMC 3229120. PMID 22215969. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229120" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229120</a> <a href="#fnref:73" class="footnote-back-ref">↩</a></p></li> <li id="fn:74"><p>Hagel JM, Krizevski R, Kilpatrick K, Sitrit Y, Marsolais F, Lewinsohn E, et al. (October 2011). "Expressed sequence tag analysis of khat (Catha edulis) provides a putative molecular biochemical basis for the biosynthesis of phenylpropylamino alkaloids". Genetics and Molecular Biology. 34 (4): 640–646. doi:10.1590/S1415-47572011000400017. PMC 3229120. PMID 22215969. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229120" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229120</a> <a href="#fnref:74" class="footnote-back-ref">↩</a></p></li> <li id="fn:75"><p>Hagel JM, Krizevski R, Kilpatrick K, Sitrit Y, Marsolais F, Lewinsohn E, et al. (October 2011). "Expressed sequence tag analysis of khat (Catha edulis) provides a putative molecular biochemical basis for the biosynthesis of phenylpropylamino alkaloids". Genetics and Molecular Biology. 34 (4): 640–646. doi:10.1590/S1415-47572011000400017. PMC 3229120. PMID 22215969. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229120" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229120</a> <a href="#fnref:75" class="footnote-back-ref">↩</a></p></li> <li id="fn:76"><p>Hagel JM, Krizevski R, Kilpatrick K, Sitrit Y, Marsolais F, Lewinsohn E, et al. (October 2011). "Expressed sequence tag analysis of khat (Catha edulis) provides a putative molecular biochemical basis for the biosynthesis of phenylpropylamino alkaloids". Genetics and Molecular Biology. 34 (4): 640–646. doi:10.1590/S1415-47572011000400017. PMC 3229120. PMID 22215969. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229120" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229120</a> <a href="#fnref:76" class="footnote-back-ref">↩</a></p></li> <li id="fn:77"><p>Hugins KB (17 July 2014). "Cathinone: History, Synthesis, and Human Applications". slideshare. Archived from the original on 4 July 2015. Retrieved 8 March 2015. <a href="https://www.slideshare.net/KevinHugins/cathinone-history-synthesis-and-human-applications" target="_blank">https://www.slideshare.net/KevinHugins/cathinone-history-synthesis-and-human-applications</a> <a href="#fnref:77" class="footnote-back-ref">↩</a></p></li> <li id="fn:78"><p>Hugins KB (17 July 2014). "Cathinone: History, Synthesis, and Human Applications". slideshare. Archived from the original on 4 July 2015. Retrieved 8 March 2015. <a href="https://www.slideshare.net/KevinHugins/cathinone-history-synthesis-and-human-applications" target="_blank">https://www.slideshare.net/KevinHugins/cathinone-history-synthesis-and-human-applications</a> <a href="#fnref:78" class="footnote-back-ref">↩</a></p></li> <li id="fn:79"><p>Hugins KB (17 July 2014). "Cathinone: History, Synthesis, and Human Applications". slideshare. Archived from the original on 4 July 2015. Retrieved 8 March 2015. <a href="https://www.slideshare.net/KevinHugins/cathinone-history-synthesis-and-human-applications" target="_blank">https://www.slideshare.net/KevinHugins/cathinone-history-synthesis-and-human-applications</a> <a href="#fnref:79" class="footnote-back-ref">↩</a></p></li> <li id="fn:80"><p>Oeri HE (May 2021). "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy". J Psychopharmacol. 35 (5): 512–536. doi:10.1177/0269881120920420. PMC 8155739. PMID 32909493. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155739" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155739</a> <a href="#fnref:80" class="footnote-back-ref">↩</a></p></li> <li id="fn:81"><p>Shulgin A (7 December 2005). "4-Hydroxy-5-methoxy-N,N-dimethyltryptamine, Psilocybe mushrooms, Psilocin". Ask Dr. Shulgin Online. Archived from the original on 7 September 2013. Retrieved 10 September 2013. <a href="http://www.cognitiveliberty.org/shulgin/blg/2005/12/4-hydroxy-5-methoxy-nn_07.html" target="_blank">http://www.cognitiveliberty.org/shulgin/blg/2005/12/4-hydroxy-5-methoxy-nn_07.html</a> <a href="#fnref:81" class="footnote-back-ref">↩</a></p></li> <li id="fn:82"><p>Oeri HE (May 2021). "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy". J Psychopharmacol. 35 (5): 512–536. doi:10.1177/0269881120920420. PMC 8155739. PMID 32909493. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155739" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155739</a> <a href="#fnref:82" class="footnote-back-ref">↩</a></p></li> <li id="fn:83"><p>Shulgin A (7 December 2005). "4-Hydroxy-5-methoxy-N,N-dimethyltryptamine, Psilocybe mushrooms, Psilocin". Ask Dr. Shulgin Online. Archived from the original on 7 September 2013. Retrieved 10 September 2013. <a href="http://www.cognitiveliberty.org/shulgin/blg/2005/12/4-hydroxy-5-methoxy-nn_07.html" target="_blank">http://www.cognitiveliberty.org/shulgin/blg/2005/12/4-hydroxy-5-methoxy-nn_07.html</a> <a href="#fnref:83" class="footnote-back-ref">↩</a></p></li> <li id="fn:84"><p>Oeri HE (May 2021). "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy". J Psychopharmacol. 35 (5): 512–536. doi:10.1177/0269881120920420. PMC 8155739. PMID 32909493. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155739" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155739</a> <a href="#fnref:84" class="footnote-back-ref">↩</a></p></li> <li id="fn:85"><p>Shulgin A (7 December 2005). "4-Hydroxy-5-methoxy-N,N-dimethyltryptamine, Psilocybe mushrooms, Psilocin". Ask Dr. Shulgin Online. Archived from the original on 7 September 2013. Retrieved 10 September 2013. <a href="http://www.cognitiveliberty.org/shulgin/blg/2005/12/4-hydroxy-5-methoxy-nn_07.html" target="_blank">http://www.cognitiveliberty.org/shulgin/blg/2005/12/4-hydroxy-5-methoxy-nn_07.html</a> <a href="#fnref:85" class="footnote-back-ref">↩</a></p></li> <li id="fn:86"><p>"Synthetic cathinones drug profile". European Monitoring Center for Drugs and Drug Addiction. EMCDDA. Archived from the original on 17 March 2015. Retrieved 8 March 2015. <a href="http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones" target="_blank">http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones</a> <a href="#fnref:86" class="footnote-back-ref">↩</a></p></li> <li id="fn:87"><p>Paškan M, Dobšíková K, Kuchař M, Setnička V, Kohout M (February 2024). "Synthesis and absolute configuration of cyclic synthetic cathinones derived from α-tetralone". Chirality. 36 (2): e23646. doi:10.1002/chir.23646. PMID 38353318. <a href="https://doi.org/10.1002%2Fchir.23646" target="_blank">https://doi.org/10.1002%2Fchir.23646</a> <a href="#fnref:87" class="footnote-back-ref">↩</a></p></li> <li id="fn:88"><p>"Synthetic cathinones drug profile". European Monitoring Center for Drugs and Drug Addiction. EMCDDA. Archived from the original on 17 March 2015. Retrieved 8 March 2015. <a href="http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones" target="_blank">http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones</a> <a href="#fnref:88" class="footnote-back-ref">↩</a></p></li> </ol>